User contributions for Tejasvi Aryaputra
Jump to navigation
Jump to search
7 February 2023
- 23:0723:07, 7 February 2023 diff hist +15,078 Lybalvi (Olanzapine and Samidorphan) No edit summary current
20 January 2023
- 17:0117:01, 20 January 2023 diff hist +3,741 N Lybalvi (Olanzapine and Samidorphan) Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Lybalvi |aOrAn=a |drugClass=combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist |indicationType=treatment |indication=schizophrenia and certain aspects of bipolar I disorder |hasBlackBoxWarning=Yes |adverseReactions=somnolence, headache, [[dry mouth], and weight increase for patients with schizophrenia. Dizziness, asthenia, constipation, [..."
- 16:1016:10, 20 January 2023 diff hist 0 N File:Package Insert Pt.2.png No edit summary current
- 16:1016:10, 20 January 2023 diff hist 0 N File:Package Insert Pt.1.png No edit summary current
- 16:1016:10, 20 January 2023 diff hist 0 N File:Drug Label 2.png No edit summary current
- 16:1016:10, 20 January 2023 diff hist 0 N File:Drug Label 1.png No edit summary current
- 16:1016:10, 20 January 2023 diff hist 0 N File:Drug Info.png No edit summary current
- 16:1016:10, 20 January 2023 diff hist 0 N File:Structure 2.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Structure 1.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Table 5 Clinical Data Trial 3.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Table 4 Clinical Data Trial 1 and 2.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Table 3 Coadmininstered Drugs.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Table 2 Adverse Reaction Trial 3.png No edit summary current
- 16:0916:09, 20 January 2023 diff hist 0 N File:Ibrexafungerp Table 1 Adverse Reactions (Trials 1 and 2).png No edit summary current
- 15:5115:51, 20 January 2023 diff hist +5,623 Ibrexafungerp No edit summary current
18 January 2023
- 06:0006:00, 18 January 2023 diff hist +4,749 Ibrexafungerp No edit summary
- 04:5604:56, 18 January 2023 diff hist +2,856 Aducanumab-avwa No edit summary current
- 04:5404:54, 18 January 2023 diff hist +2,211 Aducanumab-avwa No edit summary
11 January 2023
- 05:4805:48, 11 January 2023 diff hist +8,233 N Ibrexafungerp Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Ibrexafungerp |aOrAn=a |drugClass=triterpenoid antifungal |indicationType=treatment |indication=vulvovaginal candidiasis |hasBlackBoxWarning=Yes |adverseReactions=nausea, dizziness, diarrhea, vomiting, and abdominal pain |blackBoxWarningTitle='''<span style="color:#FF0000;">RISK OF EMBRYO-FETAL TOXICITY</span>''' |blackBoxWarningBody=<BR> *BREXAFEMME is contraindicated in pregn..."
10 January 2023
- 21:5921:59, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 8 Study 2 Biomarkers.png No edit summary current
- 21:5921:59, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 7 Clinical Results Study 1.png No edit summary current
- 21:5921:59, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 6 Study 1 Biomarkers.png No edit summary current
- 21:5921:59, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 5 Adverse Reactions.png No edit summary current
- 21:5921:59, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 4 ARIA Classification.png No edit summary current
- 21:5821:58, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 3 Dosing Modifciations.png No edit summary current
- 21:5821:58, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 2 Dosing Monitoring.png No edit summary current
- 21:5821:58, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Table 1 Dosing.png No edit summary current
- 21:5821:58, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Study 3 Biomarkers.png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Package Insert Cont..png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Package Insert.png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Figure 4 Clinical Studies.png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Figure 3 Clinical Studies.png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Figure 2 Clinical Studies.png No edit summary current
- 21:5721:57, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Figure 1 Clinical Studies.png No edit summary current
- 21:5621:56, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Drug Label (3 mL).png No edit summary current
- 21:5621:56, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Drug Label (1.7 mL).png No edit summary current
- 21:5621:56, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Drug Cont..png No edit summary current
- 21:5621:56, 10 January 2023 diff hist 0 N File:Aducanumab-avwa Drug Info .png No edit summary current
5 January 2023
- 17:3117:31, 5 January 2023 diff hist +1 Aducanumab-avwa No edit summary
- 17:2917:29, 5 January 2023 diff hist +18,474 N Aducanumab-avwa Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Aducanumab-avwa |aOrAn=an |drugClass=amyloid beta-directed antibody |indicationType=treatment |indication=treat Alzheimer’s disease |adverseReactions=ARIA-H microhemorrhage, fall, ARIA-Edema, ARIA-H superficial siderosis, and headache |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>..."
- 05:4305:43, 5 January 2023 diff hist +2,942 Asparaginase erwinia chrysanthemi (recombinant)-rywn No edit summary current
3 January 2023
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Table 5 Clinical Studies.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Table 4 Pharmacokinetics.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Table 3 Adverse Reactions.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Table 2 Dosage Modifications.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Table 1 Dosages.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Drug Label 2.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Drug Label 1.png No edit summary current
- 13:4613:46, 3 January 2023 diff hist 0 N File:Rylaze Drug Insert.png No edit summary current
- 13:3613:36, 3 January 2023 diff hist +84 Asparaginase erwinia chrysanthemi (recombinant)-rywn No edit summary
- 13:3113:31, 3 January 2023 diff hist +4,725 Asparaginase erwinia chrysanthemi (recombinant)-rywn No edit summary
29 December 2022
- 21:1621:16, 29 December 2022 diff hist +5,755 Asparaginase erwinia chrysanthemi (recombinant)-rywn No edit summary
- 19:1219:12, 29 December 2022 diff hist +6,304 N Asparaginase erwinia chrysanthemi (recombinant)-rywn Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Asparaginase erwinia chrysanthemi (recombinant)-rywn |aOrAn=an |drugClass=asparagine specific enzyme |indicationType=treatment |indication=acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen |adverseReactions=musculoskeletal pain, febrile neutropenia, hypokalemia, abnorm..."
12 September 2022
- 00:0900:09, 12 September 2022 diff hist +5,125 Finerenone No edit summary current
6 September 2022
- 00:1600:16, 6 September 2022 diff hist 0 N File:Finerenone Table 4 Clinical Studies.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Table 3 Adverse Reactions.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Table 2 Dosage Adjustments.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Table 1 Dosage.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Structure 2.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Structure.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Figure 2 Clinical Studies.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Figure 1 Clincal Studies.png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Drug Label (20 mg).png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Drug Label (10 mg).png No edit summary current
- 00:1500:15, 6 September 2022 diff hist 0 N File:Finerenone Drug Info Pt.3.png No edit summary current
- 00:1400:14, 6 September 2022 diff hist 0 N File:Finerenone Drug Info Pt.2.png No edit summary current
- 00:1400:14, 6 September 2022 diff hist 0 N File:Finerenone Drug Info.png No edit summary current
5 September 2022
- 21:0421:04, 5 September 2022 diff hist +2,463 Finerenone No edit summary
- 05:4005:40, 5 September 2022 diff hist +10,703 N Finerenone Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Finerenone |aOrAn=a |drugClass=mineralocorticoid receptor antagonist |indicationType=prophylaxis |indication=the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes |adverseReactions=hypotension, hyperkalemia, and hyponatremia |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF00..."
- 02:3402:34, 5 September 2022 diff hist +4,777 Fexinidazole No edit summary current
- 02:1102:11, 5 September 2022 diff hist 0 N File:Fexinidazole Table 6 Success Rate.png No edit summary current
- 02:1102:11, 5 September 2022 diff hist 0 N File:Fexinidazole Table 5 Pharmocokinetics.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Table 4 Drug Interactions Pt.4.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Table 3 Drug Interactions Pt.1.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Table 2 Adverse Reactions Pt.2.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Table 2 Adverse Reactions.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Table 1 Dosage.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Packaging Label.png No edit summary current
- 02:1002:10, 5 September 2022 diff hist 0 N File:Fexinidazole Packaging Info Pt.2.png No edit summary current
- 02:0902:09, 5 September 2022 diff hist 0 N File:Fexinidazole Packaging Info Pt.1.png No edit summary current
- 02:0902:09, 5 September 2022 diff hist 0 N File:Fexinidazole Chemical Structure Pt.2.png No edit summary current
- 02:0902:09, 5 September 2022 diff hist 0 N File:Fexinidazole Chemical Structure.png No edit summary current
- 02:0802:08, 5 September 2022 diff hist +6,437 Belumosudil No edit summary current
- 01:3201:32, 5 September 2022 diff hist +15,982 N Fexinidazole Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Fexinidazole |aOrAn=a |drugClass=nitroimidazole antimicrobial |indicationType=treatment |indication=human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense |adverseReactions=hypocalcemia, upper abdominal pain, insomnia, dyspepsia, decreased appetite, hyperkalemia, back pain, nausea, dizziness, asthenia, tremor, and headache...."
30 August 2022
- 01:3401:34, 30 August 2022 diff hist 0 N File:Belumosudil Table 2 Adverse Reactions.png No edit summary current
- 01:3301:33, 30 August 2022 diff hist 0 N File:Belumosudil Table 5 Clinical Data.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Table 4 Patient Pop.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Table 3 Lab Abnormalties.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Table 2 Adverse Reactions Pt. 2.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Table 1 Dosage.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Structure 2.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Structure.png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Package Insert Pt.2 .png No edit summary current
- 01:3201:32, 30 August 2022 diff hist 0 N File:Belumosudil Package Insert.png No edit summary current
- 01:3101:31, 30 August 2022 diff hist 0 N File:Belumosudil Drug Label.png No edit summary current
- 01:3101:31, 30 August 2022 diff hist 0 N File:Belumosudil Drug Insert Pt.2.png No edit summary current
- 01:3101:31, 30 August 2022 diff hist 0 N File:Belumosudil Drug Insert.png No edit summary current
- 01:2501:25, 30 August 2022 diff hist +5,821 Odevixibat No edit summary current
- 01:1301:13, 30 August 2022 diff hist 0 N File:Odevixibat Structure.png No edit summary current
- 00:5500:55, 30 August 2022 diff hist +3,257 Belumosudil No edit summary